课题基金 / 基金详情

Prevention of the Complications of Bleeding Disorders Through HTCS

Prevention of the Complications of Bleeding Disorders Through HTCS
通过 HTCS 预防出血性疾病并发症
批准号:
7279174
负责人:
Barbara A Konkle
金额:
$87.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-30 至 2011-09-29

项目摘要

项目成果

Barbara A Konkle的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):血友病是一种遗传性出血性疾病,由凝血因子VIII或因子IX缺乏引起,血管性血友病(VWD)是一种遗传性出血性疾病,由血管性血友病蛋白减少或异常引起。这些出血性疾病导致自发性和创伤诱导性出血。该项目的目的是通过地区血友病治疗中心(HTC)网络预防出血性疾病的并发症。由DE,MD,PA,VA,WV和DC区域III的15个HTC组成,为3,061名出血性疾病患者提供服务。该项目的主要研究者和重要贡献者在治疗出血性疾病患者方面拥有丰富的经验,并得到多学科团队的支持。每个HTC都是一个专业的预防、诊断和治疗计划,为患有出血性疾病的儿童、青少年和成人提供评估、教育、研究、监测、外展、咨询和管理。综合护理已被证明可以降低血友病男性的死亡率。在这一成功的基础上,并通过CDC的通用数据收集研究使用数据,该网络准备回答与遗传性出血性疾病患者的最佳护理和预防策略相关的关键问题。第三区网络与全国性的卫生技术委员会系统合作,将通过以下具体目标促进对健康促进和预防疾病、伤害和残疾的理解:1)通过以下方式加强预防活动和改善成果:扩大第三区卫生技术委员会在UDC研究中的参与,并利用收集的数据解决研究问题,包括:a)农村或城市居住是否影响UDC参与和HTC资源的利用?B)中度血友病患者的关节功能是否比接受一级或改良一级预防的重度血友病患者差?2)维持区域性高血压病患者网络,以便通过以下方式收集数据和实施预防战略:提供全面护理,减少出血性疾病的并发症;制定方案,扩大高血压病患者人群,包括妇女和少数民族;为新的和现有的高血压病工作人员提供培训资源;为其他医疗服务提供者提供教育资源。3)通过宾夕法尼亚大学核心中心实施DC支持的区域活动,与国家核心中心网络合作,通过以下方式实施这些项目活动和研究的目标:促进HTC之间的沟通;维持区域执行委员会;组织年度区域会议;监督分包HTC;担任DC、妇幼保健局、国家血友病基金会和HTC之间的联络人;在全国HTC网络中共享研究数据;并参与CDC协调委员会。
英文摘要
DESCRIPTION (provided by applicant): Hemophilia is an inherited bleeding disorder resulting from a deficiency of coagulation factor VIII or factor IX and von Willebrand Disease (VWD) is an inherited bleeding disorder resulting from decreased or abnormal von Willebrand protein. These bleeding disorders result in both spontaneous and trauma-induced bleeding. The purpose of this project is to prevent complications of bleeding disorders through the network of Region hemophilia treatment centers (HTCs). Consisting of 15 HTCs in DE, MD, PA, VA, WV, and DC Region III serves 3,061 individuals with bleeding disorders. The principal investigator and significant contributors for this project have extensive experience in caring for individuals with bleeding disorders and are supported by a multi-disciplinary team. Each HTC is a specialty, prevention, diagnostic and treatment program providing assessment, education, research, surveillance, outreach, consultation, and management to children, adolescents, and adults with bleeding disorders. Comprehensive care has been shown to decrease mortality n men with hemophilia. Building on this success and using data through the CDC's Universal Data Collection study, this network is poised to answer key questions related to optimal care and prevention strategies for patients with inherited bleeding disorders. Working collaboratively with the nationwide system of HTCs, the Region III network will foster the understanding of health promotion and prevention of disease, injury and disability by the following Specific Aims: 1) To enhance prevention activities and improve outcomes by: expanding Region III HTC participation in the UDC study and utilizing data collected to address research questions, including: a) Does rural or urban residence impact UDC participation and utilization of HTC resources? b) Do patients with moderate hemophilia have worse joint function than patients with severe disease on primary or modified primary prophylaxis? 2) To maintain the regional network of HTCs to allow data collection and implementation of prevention strategies by: providing comprehensive care to reduce complications from bleeding disorders; developing programs to expand the HTC patient populations, including women and minorities; facilitating training resources for new and established HTC staff; and providing educational resources for other medical providers. 3) To implement DC supported regional activities through the University of Pennsylvania Core Center to collaborate with a national network of Core Centers to implement the objectives of these project activities and studies by: facilitating communication between the HTCs; maintaining a Regional Executive Committee; organizing an annual Regional Meeting; providing oversight to the subcontracting HTCs; serving as a liaison between the DC, Maternal and Child Health Bureau, National Hemophilia Foundation and HTCs; sharing research data throughout the nationwide HTC network; and participating in the CDC Coordinating Committee.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
von Willebrand Factor in Sickle Cell Disease Pathophysiology
  • 批准号:
    9302585
  • 项目类别:
  • 资助金额:
    $14.88万
  • 财政年份:
    2016
  • 负责人:
    Barbara A Konkle
  • 依托单位:
A Pilot Study of N-acetylcysteine in Sickle Cell Disease Vaso-Occlusive Crisis
  • 批准号:
    9126589
  • 项目类别:
  • 资助金额:
    $39.75万
  • 财政年份:
    2015
  • 负责人:
    Barbara A Konkle
  • 依托单位:
von Willebrand Factor in Sickle Cell Disease Pathophysiology
  • 批准号:
    9000165
  • 项目类别:
  • 资助金额:
    $72.91万
  • 财政年份:
    2012
  • 负责人:
    Barbara A Konkle
  • 依托单位:
von Willebrand Factor in Sickle Cell Disease Pathophysiology
  • 批准号:
    8606884
  • 项目类别:
  • 资助金额:
    $73.13万
  • 财政年份:
    2012
  • 负责人:
    Barbara A Konkle
  • 依托单位:
海外基金